Oncology Central

Keytruda® gets the green light from NICE for untreated lung cancer

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending that Keytruda® (pembrolizumab), in combination with Alimta® (pemetrexed) and platinum chemotherapy, should be available through the Cancer Drugs Fund as a treatment option for certain patients with untreated non-small-cell lung cancer (NSCLC).
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.